Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: Two case reports
| Autor: | Agrillo A, Nastro Siniscalchi E, Facchini A, Filiaci F, Claudio Ungari |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
Male
Antiangiogenic Bisphosphonates Jaws Osteonecrosis Sunitinib Medicine (all) Pharmacology (medical) Indoles sunitinib Angiogenesis Inhibitors Bone Neoplasms Nephrectomy Fatal Outcome Risk Factors Humans antiangiogenic bisphosphonates jaws osteonecrosis Pyrroles Carcinoma Renal Cell Aged Bone Density Conservation Agents Diphosphonates Kidney Neoplasms Treatment Outcome Disease Progression Bisphosphonate-Associated Osteonecrosis of the Jaw Tomography X-Ray Computed |
| Zdroj: | Europe PubMed Central Scopus-Elsevier |
| Popis: | Osteonecrosis of the jaw (ONJ) is an unremitting adverse outcome associated with bisphosphonate therapy, primarily intravenously administered, in patients with bone metastases from solid tumors, multiple myeloma and osteometabolic diseases. From 2003 many cases of bisphosphonates related osteonecrosis of the jaw (BRONJ) have been reported in literature. Sunititnib is a novel anticancer agent used in gastrointestinal cancers and renal cancers resistant to imatinib. Recent reports describe the onset of ONJ in patients treated with both sunitinib and bisphosponates. A case of osteonecrosis of the jaw related to sunitinib, without association of bisphosphonate (BP) medications has been recently reported. A recent hypothesis suggests that antiangiogenic drugs such as sunitinib could cause ONJ even without the association with BPs. We describe a case of two patients affected by renal carcinoma under BP and sunitinib medication who developed stage III bisphosphonates-related osteonecrosis of the jaw (BRONJ). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|